Results 131 to 140 of about 2,122 (167)

Fastrack: pushing the boundaries of brand extension

Emerald Emerging Markets Case Studies, 2015
Subject area Marketing. Study level/applicability MBA students. Case overview Titan Industries Limited is the world's fifth-largest wristwatch manufacturer and India's leading producer of watches under the Titan, Fastrack, Sonata, Nebula, Raga, Regalia, Octane and Xylys brand names.
S. Prabhakar, Madhavi A Lokhande
semanticscholar   +2 more sources

Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.

The Lancet Oncology
Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surgical resection. The FASTRACK II clinical trial investigated the efficacy of SABR for primary renal cell cancer in a phase 2 trial.This international, non-randomised, phase 2 study was conducted in seven ...
Shankar Siva, M. Bressel, M. Sidhom, S. Sridharan, B. Vanneste, R. Davey, R. Montgomery, J. Ruben, F. Foroudi, B. Higgs, Charles Lin, A. Raman, N. Hardcastle, M. Hofman, R. De Abreu Lourenço, M. Shaw, P. Mancuso, Daniel Moon, Lih-Ming Wong, N. Lawrentschuk, S. Wood, N. Brook, Tomas Kron, Jarad Martin, David Pryor   +24 more
semanticscholar   +4 more sources

Advancements in String-Searching Algorithms Fastrack-StringSearch: A Novel Approach

2024 15th International Conference on Computing Communication and Networking Technologies (ICCCNT)
String matching plays a crucial role in applications, such involving retrieval of information, data mining, natural language processing, and biology with computation. However, existing string-matching algorithms, including the Naïve Method, KMP Algorithm,
Amruth Ashok, Ramanan Ravichandran, Rhea Paul, C. Vimal, Meena Belwal   +4 more
semanticscholar   +2 more sources

Dose-effect Relationship of Kidney Function After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: Trog 15.03 Fastrack Ii.

International Journal of Radiation Oncology*Biology*Physics
Stereotactic ablative body radiotherapy (SABR) is a novel option to treat primary renal cell carcinoma. However, a high radiation dose may be received by the treated kidney, which may affect its function posttreatment. This study investigates the dose-effect relationship of kidney SABR with posttreatment renal function.This was a prespecified secondary
M. Gaudreault, N. Hardcastle, P. Jackson, Lachlan McIntosh, B. Higgs, David Pryor, M. Sidhom, R. Dykyj, Alisha Moore, T. Kron, Shankar Siva   +10 more
semanticscholar   +3 more sources

Shorter hospital stay associated with fastrack postoperative care pathways and laparoscopic intestinal resection are not associated with increased physical activity

Colorectal Disease, 2004
AbstractObjective  Recent prospective studies have shown that ‘fast track’ postoperative care protocols (FT) can reduce hospitalization after major intestinal surgery to 4.5 days, as compared to the 7–10 days with traditional management (TR) and 2.5 days after laparoscopic surgery (LC). We used computerized actigraphy (CA) to evaluate physical activity
M. Zutshi, Conor P. Delaney, A. J. Senagore, V. Fazio   +3 more
semanticscholar   +3 more sources

Ultra-Hypofractionated Stereotactic Ablative Body Radiotherapy (SABR) for Primary Renal Cell Carcinoma: Pooled Outcomes from the FASTRACK and FASTRACK II Clinical Trials

International Journal of Radiation Oncology*Biology*Physics
S. Siva, M. Ali, D. Moon, N. Hardcastle, T. Kron, B. Higgs, F. Foroudi, J. Ruben, J.M. Martin, S. Sridharan, R. Montgomery, R. Davey, C. Lin, M. Shaw, M. Sidhom, B. Vanneste, D. Murphy, N. Lawrentschuk, S. Wood, D.I. Pryor   +19 more
semanticscholar   +2 more sources

NP012 FASTRACK Cardiac Surgery

Canadian Journal of Cardiology, 2012
C. Kee, M. Kroh, B. Kiaii
semanticscholar   +2 more sources

The impact of brand and quality on Fastrack watch customer satisfaction

International Journal of Research in Marketing Management and Sales
M. Ramu, Madhavan A
semanticscholar   +2 more sources

235: Dose-effect relationship after SABR for primary renal cell carcinoma: FASTRACK II (NCT02613819)

Radiotherapy and Oncology
M. Gaudreault, N. Hardcastle, P. Jackson, Lachlan McIntosh, B. Higgs, David Pryor, M. Sidhom, R. Dykyj, Alisha Moore, T. Kron, Shankar Siva   +10 more
semanticscholar   +2 more sources

Re: Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Non-randomised Phase 2 Trial.

European Urology
Aimin Jiang, Ying Liu, Chen Cai, Peng Luo, Linhui Wang   +4 more
semanticscholar   +3 more sources